Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
7,599.96
(
0.26%
)
US TECH 100
29,678.20
(
-0.11%
)
Dow Jones
51,078.88
(
0.00%
)
Brent Oil
93.05
(
-3.05%
)
Bitcoin
69,179.98
(
-3.07%
)
News Focus
News Focus
Post# of 257684
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123050
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: indigokid post# 208171

Wednesday, 01/18/2017 6:59:27 PM

Wednesday, January 18, 2017 6:59:27 PM

Post# of 257684
Re: MNTA's Humira FoB

I concur with your post on all counts—including the sufficiency of the phase-3 trial design (as noted in #msg-127956688).

If MNTA does end up with the only interchangeable Humira FoB for the US market, the upside is colossal—whether or not the program is partnered.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today